Clinical trial
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00101920 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00101920 |
|---|---|
| Title | ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) |
| Official title | A Clinical Trial of the Safety and Efficacy of ABX-EGF as Second Line Treatment for Advanced Non-Small Lung Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer |
| Intervention type | Drug |
| Interventions | ABX-EGF |
| Enrollment | 50 |
| Start date | Jun 1, 2003 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Jan 19, 2005 |
| Last update posted | Oct 15, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: